Showing 1231-1240 of 1511 results for "".
- Johnson & Johnson Vision to Launch Acuvue Oasys Max 1-Day Contact Lenses in Several Marketshttps://modernod.com/news/johnson-johnson-vision-to-launch-acuvue-oasys-max-1-day-contact-lenses-in-several-markets/2480914/Johnson & Johnson Vision announced it has received FDA clearance, Health Canada approval, and completed CE Mark activities for its latest contact lens, Acuvue Oasys Max 1-Day and Acuvue Oasys Max 1-Day Multifocal. The announcement comes during the 125th Annual AOA Congress and 54th<
- Johnson & Johnson Vision Appoints Peter Menziuso as Company Group Chairmanhttps://modernod.com/news/johnson-johnson-vision-appoints-peter-menziuso-as-company-group-chairman/2480835/Johnson & Johnson Vision announced the appointment of Peter Menziuso as Company Group Chairman.
- Johnson & Johnson Vision Introduces Next-Generation TearScience Activator Clear for Treatment of MGDhttps://modernod.com/news/johnson-johnson-vision-introduces-next-generation-tearscience-activator-clear-for-treatment-of-mgd/2480795/Johnson & Johnson Vision announced the availability of the next-generation TearScience Activator Clear. Building on the legacy of the TearScience LipiFlow Thermal Pulsation System—a fully automated treatment for meibomian gland dysfunction (MGD)—Johnson & Johnson Vis
- Johnson & Johnson Vision Receives FDA Approval for First Drug-Eluting Contact Lens—Acuvue Theravision with Ketotifenhttps://modernod.com/news/johnson-johnson-vision-receives-fda-approval-for-first-drug-eluting-contact-lens-acuvue-theravision-with-ketotifen/2480676/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Theravision with Ketotifen (etafilcon A drug-eluting contact lens with ketotifen), the first drug-eluting contact lens. Each lens contains 19 mcg ketotifen, an antihistamine. Acuv
- Johnson & Johnson Vision to Present New Data at AAO Demonstrating Benefits That New Innovations in Cataract Surgery Will Provide to Physicians and Patientshttps://modernod.com/news/johnson-johnson-vision-to-present-new-data-at-aao-demonstrating-benefits-that-new-innovations-in-cataract-surgery-will-provide-to-physicians-and-patients/2480412/Johnson & Johnson Vision will present a range of company-sponsored studies supporting new innovations in its cataract
- Johnson & Johnson Vision Presents Findings from New Myopia Research and Highlights Latest Contact Lens Innovations for Patients with Presbyopia at Academy 2021https://modernod.com/news/johnson-johnson-vision-presents-findings-from-new-myopia-research-and-highlights-latest-contact-lens-innovations-for-patients-with-presbyopia-at-academy-2021/2480391/Johnson & Johnson Vision announced that new myopia data outcomes will be presented at the upcoming 2021 American Academy of Optometry (AAO) annual
- Johnson & Johnson Vision Showcases New Veritas Vision System and Presents Latest Clinical Data at ESCRS 2021https://modernod.com/news/johnson-johnson-vision-showcases-new-veritas-vision-system-and-presents-latest-clinical-data-at-escrs-2021/2480324/Johnson & Johnson Vision will showcase the new Veritas Vision System and a range of clinical data relating
- Johnson & Johnson Vision Receives Approval in Canada for Acuvue Abiliti 1-Day Lenseshttps://modernod.com/news/johnson-johnson-vision-receives-approval-in-canada-for-acuvue-abiliti-1-day-lenses/2479496/Johnson & Johnson Vision received approval from Health Canada for Acuvue Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management. Abiliti 1-Day lenses are a new option of daily wear, single-use, disposable lenses that have the potential to slow the progression of myopia and are specifical
- Johnson & Johnson Vision Launches Veritas Vision Systemhttps://modernod.com/news/johnson-johnson-vision-introduces-veritas-vision-system-with-features-to-address-key-unmet-needs-in-cataract-surgery/2479401/Johnson & Johnson Vision announced the global availability of the Veritas Vision System, a next-generation phacoemulsification system designed to address three critical areas: patient safety, surgeon efficiency and comfort. The company will offer live demos of the new system in a wet lab at t
- Johnson & Johnson Vision to Present Scientific Data Validating Improved Surgical Outcomes and Legacy MGD Treatment at ASCRShttps://modernod.com/news/johnson-johnson-vision-to-present-scientific-data-validating-improved-surgical-outcomes-and-legacy-mgd-treatment-at-ascrs/2479387/Johnson & Johnson Vision announced that 21 company-sponsored studies supporting cataract surgery outcomes will be presented at the 2021 American Society of Cataract and Refractive Surgery (ASCRS) and American Society of Ophthalmic Administrators (ASOA) Annual Meeting in Las Vegas Nevada, July